Sarepta Therapeuticsgained 70% in August and has seen another 30% increase in September. This run can be attributed to Sarepta's potentially game-changing drug for muscular dystrophy, currently in phase 2 trials. Early reports have been positive, with a significantly slower decline in function and an increase in muscle fibers. While the drug won't undo damage, it could greatly improve the outlook for sufferers.
October will see the release of 48-week data, and if it substantiates the 36-week data, expect this stock's run to continue. Watch the following video for Fool.com analyst David Williamson's full report.
While you can make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, and we also reveal some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article This Drug Could Be a Game-Changer for Sarepta (and a Savior for Thousands) originally appeared on Fool.com.
Brenton Flynn and Dave Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.